ArticleWellcome open research2025

Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).

Victoria Babirye Tumusiime et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.